Bora CDMO Bora CDMO

X
[{"orgOrder":0,"company":"Rubio Laboratories","sponsor":"Aspargo Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aspargo Acquires Bandol Sildenafil Spray, Currently Marketed In Spain","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"SPAIN","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals by Rubio Laboratories

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            BANDOL®, offered in a convenient and discreet metered dose container that delivers the equivalent of 12.5 mg of Sildenafil per actuation, is manufactured in Spain and is prescribed predominantly by primary care physicians and urologists.

            Lead Product(s): Sildenafil Citrate

            Therapeutic Area: Psychiatry/Psychology Product Name: Bandol

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Aspargo Laboratories

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition May 04, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY